Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Froehner

Showing results (1-10 of 191) with videos related to

Pageof 20
Sort By:
The Journal of Urology|July 24, 2012
Editorial commentMichael Froehner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Life expectancy estimation by nomogramMichael Froehner
European Urology|June 9, 2026
Re: Brian F. Chapin, Marc Smaldone, Amado J. Zurita, et al. A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. Eur Urol. In Press. http://dx.doi.org/10.1016/j.eururo.2026.02.011Michael Froehner
Urology|September 7, 2021
EDITORIAL COMMENTMichael Froehner
JAMA|January 7, 2010
Age and prostate cancer survivalMichael Froehner
The Journal of Urology|October 9, 2003
Re: Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extensionMichael Froehner
European Urology|November 17, 2007
Editorial comment on: diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per literMichael Froehner
Cancer|September 20, 2013
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancerMichael Froehner
European Urology|April 3, 2024
Re: Marc-Oliver Grimm, Mototsuga Oya, Toni K. Choueiri, et al. Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial. Eur Urol 2024;85:8-12Michael Froehner
The Journal of Urology|January 18, 2011
Editorial commentMichael Froehner
Pageof 20

Showing results (1-10 of 191) with videos related to

Sort By:
Pageof 20
The Journal of Urology|July 24, 2012
Editorial commentMichael Froehner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Life expectancy estimation by nomogramMichael Froehner
European Urology|June 9, 2026
Re: Brian F. Chapin, Marc Smaldone, Amado J. Zurita, et al. A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. Eur Urol. In Press. http://dx.doi.org/10.1016/j.eururo.2026.02.011Michael Froehner
Urology|September 7, 2021
EDITORIAL COMMENTMichael Froehner
JAMA|January 7, 2010
Age and prostate cancer survivalMichael Froehner
The Journal of Urology|October 9, 2003
Re: Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extensionMichael Froehner
European Urology|November 17, 2007
Editorial comment on: diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per literMichael Froehner
Cancer|September 20, 2013
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancerMichael Froehner
European Urology|April 3, 2024
Re: Marc-Oliver Grimm, Mototsuga Oya, Toni K. Choueiri, et al. Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial. Eur Urol 2024;85:8-12Michael Froehner
The Journal of Urology|January 18, 2011
Editorial commentMichael Froehner
Pageof 20